Roivant Sciences (ROIV) Competitors $16.03 -0.09 (-0.56%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$15.95 -0.08 (-0.50%) As of 10/8/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ROIV vs. ONC, INSM, BNTX, TEVA, GMAB, SMMT, ASND, VTRS, RDY, and MRNAShould you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Roivant Sciences vs. Its Competitors BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna BeOne Medicines (NASDAQ:ONC) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Which has better valuation and earnings, ONC or ROIV? Roivant Sciences has lower revenue, but higher earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeOne Medicines$3.81B10.10-$644.79M-$1.73-202.94Roivant Sciences$23.23M471.17-$171.98M-$0.70-22.90 Do analysts recommend ONC or ROIV? BeOne Medicines presently has a consensus price target of $340.30, indicating a potential downside of 3.07%. Roivant Sciences has a consensus price target of $19.94, indicating a potential upside of 24.38%. Given Roivant Sciences' higher possible upside, analysts clearly believe Roivant Sciences is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Is ONC or ROIV more profitable? BeOne Medicines has a net margin of -3.89% compared to Roivant Sciences' net margin of -2,111.79%. BeOne Medicines' return on equity of -1.22% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets BeOne Medicines-3.89% -1.22% -0.72% Roivant Sciences -2,111.79%-15.90%-14.95% Do insiders & institutionals hold more shares of ONC or ROIV? 48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, ONC or ROIV? BeOne Medicines has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Does the media favor ONC or ROIV? In the previous week, BeOne Medicines and BeOne Medicines both had 9 articles in the media. Roivant Sciences' average media sentiment score of 0.83 beat BeOne Medicines' score of 0.61 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRoivant Sciences beats BeOne Medicines on 9 of the 15 factors compared between the two stocks. Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROIV vs. The Competition Export to ExcelMetricRoivant SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.01B$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-22.9021.5785.3527.60Price / Sales471.17271.49539.78202.41Price / CashN/A47.1237.9261.55Price / Book2.1510.1413.016.76Net Income-$171.98M-$52.31M$3.30B$275.88M7 Day Performance0.31%5.14%4.34%2.81%1 Month Performance18.92%14.68%9.49%9.24%1 Year Performance39.27%30.98%84.83%35.42% Roivant Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROIVRoivant Sciences3.5482 of 5 stars$16.03-0.6%$19.94+24.4%+42.1%$11.01B$23.23M-22.90860Analyst ForecastInsider TradeONCBeOne Medicines1.469 of 5 stars$344.53+0.2%$336.30-2.4%N/A$37.69B$3.81B-199.1511,000Analyst ForecastINSMInsmed3.2682 of 5 stars$158.28+0.7%$149.06-5.8%+126.7%$33.22B$363.71M-27.721,271Analyst ForecastBNTXBioNTech2.651 of 5 stars$105.16-0.3%$134.56+28.0%-11.7%$25.36B$2.98B-65.726,772Positive NewsTEVATeva Pharmaceutical Industries3.0112 of 5 stars$19.99-0.1%$25.57+27.9%+15.3%$22.95B$16.54B-124.9436,830Analyst ForecastAnalyst RevisionGMABGenmab A/S4.3435 of 5 stars$33.31-0.7%$40.80+22.5%+38.8%$21.55B$3.12B16.742,682Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics3.1722 of 5 stars$22.15+3.4%$31.29+41.2%+18.5%$15.92B$700K-21.93110Analyst ForecastASNDAscendis Pharma A/S3.0302 of 5 stars$210.83+3.3%$244.36+15.9%+59.1%$12.59B$393.54M-40.861,017News CoverageAnalyst ForecastHigh Trading VolumeVTRSViatris1.678 of 5 stars$10.13-0.6%$10.40+2.7%-11.9%$11.88B$14.74B-3.4932,000Analyst ForecastRDYDr. Reddy's Laboratories3.282 of 5 stars$14.12-0.3%$16.95+20.0%-11.1%$11.82B$3.81B21.3927,811News CoveragePositive NewsAnalyst ForecastMRNAModerna4.3224 of 5 stars$27.54-3.3%$41.81+51.8%-52.2%$11.08B$3.24B-3.665,800Analyst Forecast Related Companies and Tools Related Companies ONC Competitors INSM Competitors BNTX Competitors TEVA Competitors GMAB Competitors SMMT Competitors ASND Competitors VTRS Competitors RDY Competitors MRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ROIV) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
